Autoimmune Lymphoproliferative Syndrome (ALPS): A Case Report by Mousa, Yazan S.
The International Journal of Medical StudentsInt J Med Students   •   2016  |  Sep-Dec  |  Vol  4  |  Issue 3 123
Case Report
Autoimmune Lymphoproliferative Syndrome (ALPS): A 
Case Report
Yazan S. Mousa.1
Abstract
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the blood, estimated at around 500 cases worldwide. 
It is characterized by a dysregulation of T-cells in the immune system, and is caused by a defect in the process that mediates leukocyte 
apoptosis. This may result in an increased risk of lymphoma and autoimmune diseases. Case: The author reports a case of an 11-year-old 
male who had been followed up since three years of age for recurrent cytopenias, occurring with intermittent breakouts of purpuric rash, 
nosebleeds, and prolonged infections. Conclusion: A probable diagnosis was made through criteria based on the First International ALPS 
workshop of 2009. This includes the presence of circulating double-negative T cells, considered the laboratory marker unique for ALPS. The 
mainstay of treatment was prednisone, given at doses varying in proportion to the severity of immunocytopenia.
osis. 
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Introduction
Autoimmune lymphoproliferative syndrome (ALPS) is an ab-
normality of lymphocyte homeostasis, caused by a disruption 
in the apoptosis pathway mediated by the FAS gene. Clinical 
sequelae are most commonly defined by a lymphoproliferative 
pattern in early disease onset age groups, and an autoimmune 
pattern in later disease onset.1
The exact incidence and prevalence of ALPS are unknown. It 
is estimated that the number exceeds 500 worldwide, but due 
to difficulty in diagnosis and features that overlap with other 
diseases, particularly Evans’ syndrome, this has not been re-
liably confirmed.2,3 ALPS has been reported among a spectrum 
of different races. A male predominance has been confirmed 
by the French ALPS cohort and the National Institutes of Health 
(NIH) cohort, with the ratio of male to female patients being 2.2 
and 1.6 respectively.1,4
About two-thirds of patients with ALPS have an identified ge-
netic defect.5 The germline mutation in the ALPS-FAS gene, also 
called tumor necrosis factor receptor superfamily member 6, 
is most commonly implicated. It is inherited in an autosomal 
dominant manner. Furthermore, about 15% to 20% of patients 
have somatic mutations in FAS (ALPS-sFAS).6-8 In these patients, 
somatic mutations are found in alpha/beta double-negative T 
(DNT) cells and also in other hematopoietic cells.9,10
Leukocyte proliferation and expanded populations result in 
lymphadenopathy, splenomegaly and, less frequently, hepato-
megaly.10 A specific staging system that can be used to predict 
the prognosis in patients with ALPS has not yet been esta-
blished. However, prognosis of lymphoproliferation is conside-
red relatively better than autoimmunity, and fewer individuals 
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Key Points:
• Autoimmune lymphoproliferative syndrome (ALPS) is a rare disor-
der of immune regulation estimated at around 500 cases worldwide. 
It results in varying degrees of autoimmunity and lymphoproliferation, 
increasing the risk for lymphoma.
• The condition remains underdiagnosed as a result of similarities with 
other combined immunocytopenias, particularly Evans’ syndrome, and 
difficulty in diagnosis.
• The presence of circulating double-negative T cells, detected using 
flow cytometric immunophenotyping, is considered the hallmark of the 
disease.
• A probable or definitive diagnosis can be made through criteria based 
on the First International ALPS workshop of 2009. Treatment and follow 
up is essentially the same with immunomodulators and/or immuno-
suppressants.
require long-term treatment with immunomodulating agents 
such as glucocorticoids, mycophenolate mofetil (MMF), rituxi-
mab and high-dose intravenous immune globulin (IVIG).11
The author hereby presents a case of an 11-year-old Asian 
male, who has been followed up since three years of age for 
recurrent cytopenias, to raise awareness for early diagnosis 
and management of ALPS. Written consent was obtained from 
the patient for the publication of material relating to them in 
this journal.
The Case
An 11-year-old Asian male developed exacerbation of his idio-
pathic thrombocytopenic purpura, which was diagnosed at age 
3 by exclusion. He had presented multiple times to the George-
town University Hospital with intermittent breakouts of purpu-
ric rash, nosebleeds, and prolonged infections since the time 
of diagnosis eight years ago. He had no other medical condi-
tions, and his family history was negative for hematological 
The International Journal of Medical Students Int J Med Students   •   2016  |  Sep-Dec  |  Vol  4  |  Issue 3124
IJMS
International Journal of 
Medical Students Case Report
and autoimmune disorders. Vital signs were stable. Successive 
physical examinations showed mild stable hepatomegaly, and 
ultrasound examination showed resolving mild splenomegaly. 
Lymphadenopathy was inappreciable.
Initial workup showed thrombocytopenia and lymphocytope-
nia. His blood counts over an eight-year follow-up period re-
turned median values of 11.9 g/dL (range: 4.3–14.6 g/dL), 146 × 
109/L (range: 2.0–494 × 109/L), and 3.30 × 109/L (range: 0.0005–
25.1 × 109/L) for hemoglobin, platelets and absolute neutrophil 
count, respectively (Table 1). Severity of hemoglobin reached a 
maximum of grade 3 (<7.0 g/dL) according to Division of Micro-
biology and Infectious diseases (DMID) pediatric toxicity tables, 
and grade 4 for platelets (<25 × 109/L) and ANC (<0.25 × 109/L). 
A bone marrow analysis returned normal results. The differen-
tial diagnosis included common variable immunodeficiency, 
hyperimmunoglobulin M syndrome, Wiskott-Aldrich syndrome, 
and hemophagocytic lymphohistiocytosis. Further evaluation 
showed evidence of positive direct and indirect coombs wi-
thout hemolysis. Anti-nuclear and antiphospholipid antibody 
levels were negative, and complement levels were within nor-
mal range. Hepatitis B and C serological tests were negative. 
Antineutrophil antibodies (specific antibodies against the poly-
morphic human neutrophil antigen) were found to be positive, 
suggesting an underlying autoimmune neutropenia. Finally, 
flow cytometry of peripheral blood revealed the presence of 
double-negative T (DNT) cells (Table 2), solidifying a diagnosis 
of probable autoimmune lymphoproliferative syndrome (ALPS). 
Pertinent positive laboratory test results showing the progres-
sion of likely diagnoses in this patient can be found in Figure 1.
Patient was fully compliant to the treatment. He elicited a favo-
rable response to intravenous immunoglobulin (IVIG) and pred-
nisolone (Figure 2). A trial of rituximab (375 mg/m2), to which 
he developed fever, chills, and flushing, was not tolerated. Ta-
ble 1 shows select values at which the patient’s counts were at 
their lowest; Point D demonstrates severe anemia after he was 
referred from a nearby emergency center with fever, vomiting, 
dehydration, and a hemoglobin level of 4.1 g/dL. Upon admis-
sion, he was given two units of packed red blood cells, in addi-
tion to two doses of IVIG and intravenous methylprednisolone 
(0.8 mg/kg every 6 hours). His counts began responding after 
the second transfusion with stabilization and then increase in 
his hemogloblin to 8.4 g/dL over four days. He was started on 
60 mg oral prednisone thrice daily, which was  tapered down 
gradually with continued improvement of symptoms after dis-
charge. As of the writing of this paper, follow-ups have seen the 
patient’s blood counts and symptoms remain relatively stable 
with the use of oral prednisone.
Discussion
The diagnosis of autoimmune lymphoproliferative syndrome 
(ALPS) is currently based on the presence of two required and 
six additional criteria.12 Required criteria include the presence 
of lymphadenopathy and/or splenomegaly, as well as elevated 
circulating alpha/beta double-negative T (DNT) cells detected 
using flow cytometric immunophenotyping, considered the ha-
llmark of the disease. These cells are very rare in healthy indivi-
duals and other immunological disorders, and typically account 
for less than 2% of the total lymphocyte count. Other lympho-
cyte subsets may also be expanded, as well as biomarkers such 
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Figure 1. Pertinent Positive Laboratory Test Results Showing the Progression of Likely Diagnoses 
in a Patient with Probable ALPS
A Trend-line showing the Relationship between Cell Counts and Prednisone Treatment may be found in 
Figure 2
Figure 2. Relationship of Prednisone Treatment to Hemoglobin, Platelet and Absolute Neutrophil 
Counts in Patient with Probable ALPS over an Eight-Year Period. A Moving Average Two-period 
Trend-line has been added (Dotted Line)
Date
[MM.DD.YY]
Hemoglobin (g/dL)
[normal: 13–17]
Platelets (× 109/L)
[normal 150–400]
Absolute neutrophil count 
(× 109/L) [normal: 2–8]
Range NA 4.3–14.6 2–494 0.5–25.1
Median NA 11.9 146 3.3
A 04.02.08 8.7 31 0.001
B 06.23.09 11.1 5 0.322
C 12.03.11 11.0 4 0.609
D 11.03.12 4.3 208 0.223
Table 1. Median, Range and Select Severe Values for Hemoglobin, Platelets and Absolute Neutro-
phils (ANC) in a Patient with Probable ALPS
Results Reference range
% Abs # (/Ul) % Abs # (/Ul)
Total T cell CD3 72.5 2,467 58.7–82.6 780–2,537
Total B cell CD20 26.4 898 8.8–27.9 118–837
Total NK cell CD16+ or CD56+/CD3- 1.3 44 4.4–28.0 70–688
T cell subsets CD3+/CD4-/CD8- 10.0 340 2.4–10.4 53–221
DNT/alpha-beta 3.4 116 0.4–1.5 8–32
CD8+/CD57+/CD3+ 333 333 <6.9 <246
B cell subsets CD20/CD5 13.3 453 0.6–10.4 16–235
CD20/CD27 6.8 231 1.4–4.9 21–111
Table 2. Lymphocyte Phenotyping Results, Showing Positive Double-Negative T (DNT) Cells in a 
Patient with Probable ALPS, the Laboratory Marker Unique to the Condition
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as vitamin B12, interleukin 10, interleukin 19, and Fas ligand 
(FAS-L) in serum.13
An abnormal lymphocyte apoptosis assay is no longer con-
sidered essential for the diagnosis of ALPS, as patients with 
both somatic FAS mutations and germline FASL mutations can 
present with normal apoptosis assays. The routine use of this 
assay is impractical as it is only offered by very few specialized 
centers.14,15 A probable ALPS diagnosis can be assumed if both 
the required criteria and any one of the secondary additional 
criteria are present.12
Lymphoid precursor proliferation tend to wax and wane for re-
asons that remain unclear, resulting in various degrees of lym-
phadenopathy and splenomegaly over the course of the disea-
se.1 Autoimmunity presents in males more often than females, 
although it may not always be apparent at the time of diagnosis 
or when lymphoid precursors are in large numbers.
The condition usually involves more than one hematopoeitic 
cell line, such as combinations of autoimmune hemolytic ane-
mia (AIHA), immune thrombocytopenia (ITP), and less com-
monly autoimmune neutropenia (AIN). Evans syndrome, the 
association of autoimmune anemia and immunological throm-
bocytopenia, can be consistent with ALPS especially with im-
munophenotyping evidence. In many patients, autoimmunity 
signifies the transition into ALPS requiring long-term therapy 
and rendering it a less-favorable prognosis.5
Over the course of the eight-year follow up our patient, he was 
found to have splenomegaly that fluctuated with time, as well 
as elevated circulating alpha/beta DNT cells at 3.4% upon lym-
phocyte phenotyping. The presence of over 3% alpha/beta DNT 
cells is seldom seen in any conditions other than ALPS.16 Po-
sitive direct Coomb’s test, indicating autoimmune hemolysis, 
and his prior diagnosis with idiopathic thrombocytopenic pur-
pura (ITP) suggested Evans’ syndrome. Furthermore, with his 
positive antineutrophil antibodies demonstrating autoimmune 
neutropenia, it was likely that an immunopancytopenia was 
present.
The aforementioned findings fulfill the revised diagnostic crite-
ria put forward by the First International ALPS workshop in 2009 
as a probable diagnosis of ALPS (Table 3). Accordingly, patients 
with probable ALPS should be treated and monitored in the 
same way as patients with a definitive diagnosis with immu-
nosuppressive and immunomodulating agents such as gluco-
corticoids, cyclosporine, rituximab and high-dose intravenous 
immune globulin (IVIG).10
Our treatment followed the general recommendations of the 
American Society of Hematology, which can be broadly applica-
ble to ALPS patients with chronic thrombocytopenia.17 The pa-
tient responded greatly to immunosuppression by prednisone 
therapy. High-dose pulse therapy with intravenous methylpred-
nisolone (≈ 5 mg/kg) followed by low-dose oral prednisone (≈ 
1 mg/kg) maintenance was used successfully for the pancyto-
penias, while tapering over several weeks to avoid the well-do-
cumented side effects of corticosteroids. G-CSF therapy (150 
micrograms, four times daily) was also shown to be favorable 
for thrombocytopenia and low ANC. Results with IVIG (1 g/kg) 
treatment was variable for thrombocytopenia. Rituximab (375 
mg/m2) was not tolerated.
Morbidity and mortality in ALPS depend on the severity of the 
autoimmune disease and development of lymphoma.18 Long-
term monitoring and follow-up is necessary to avoid complica-
tions associated with the disease and relevant therapy. It is ne-
cessary to understand the natural history of this rare disorder to 
plan for early interventions, such as the use of myocephenolate 
mofetil (MMF), sirolimus, or stem cell transplantation.19 Finally, 
the risk-benefit ratio must be assessed before any decision that 
relates to therapy is commenced.
References
1. Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, et al. Natural history 
of autoimmune lymphoproliferative syndrome associated with FAS gene mu-
tations. Blood. 2014 Mar 27;123(13):1989-99. 
2. Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune 
lymphoproliferative syndrome in children with Evans syndrome: a multi-ins-
titutional study. Blood. 2010 Mar 18;115(11):2142-5. 
3. Stepensky P, Rensing-Ehl A, Gather R, Revel-Vilk S, Fischer U, Nabhani S, 
et al. Early-onset Evans syndrome, immunodeficiency, and premature immu-
nosenescence associated with tripeptidyl-peptidase II deficiency. Blood. 2015 
Jan 29;125(5):753-61. 
4. Neven B, Magerus-Chatinet A, Florkin B, Gobert D, Lambotte O, De Somer L, 
et al. A survey of 90 patients with autoimmune lymphoproliferative syndro-
me related to TNFRSF6 mutation. Blood. 2011 Nov 3;118(18):4798-807. 
5. Madkaikar M, Mhatre S, Gupta M, Ghosh K. Advances in autoimmune lym-
phoproliferative syndromes. Eur J Haematol. 2011 Jul;87(1):1-9. 
6. Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur 
AM, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mu-
Required criteria Criteria present
Chronic (>6 months), nonmalignant, noninfectious lymphadenopathy and/or sple-
nomegaly
Yes
Elevated CD3+ TCRαβ+ CD4- CD8- DNT cells (>1.5% of total lymphocytes or >2.5% of 
CD3+ lymphocytes) in the setting of normal or elevated lymphocyte counts
Yes
Additional criteria Criteria present
Primary
Defective lymphocyte apoptosis in 2 separate assays No
Somatic or germline pathogenic mutation in FAS, FASLG, or CASP10 No
Secondary
Elevated plasma sFASL levels, plasma IL-10 levels, serum or plasma vitamin B12 
levels or plasma IL-18 levels
No
Typical immunohistologic findings as reviewed by a hematopathologist No
Autoimmune cytopenia (hemolytic anemia, thrombocytopenia, or neutropenia) 
with elevated IgG levels (polyclonal hypergammaglobulinemia)
Yes
Family history of a nonmalignant/noninfectious lymphoproliferation with or wi-
thout autoimmunity
No
Definitive diagnosis: Both required criteria plus one primary accessory criterion. No
Probable diagnosis: Both required criteria plus one secondary accessory criterion. Yes
Table 3. Revised Diagnostic Criteria for ALPS Based on the First International ALPS Workshop of 2009, 
Showing Criteria Fulfilling a Probable ALPS Diagnosis in this Patient
The International Journal of Medical Students Int J Med Students   •   2016  |  Sep-Dec  |  Vol  4  |  Issue 3126
IJMS
International Journal of 
Medical Students Case Report
Mousa YS. Autoimmune Lymphoproliferative Syndrome (ALPS): A Case Report
Acknowledgments
The author would like to thank Amal M. Abu-Ghosh, MD and the kind staff at the Lombardi Comprehensive Cancer Center for their help 
and guidance during his away rotation at the Medstar Georgetown University Hospital in Washington, DC.
Conflict of Interest Statement & Funding
The author has no funding, financial relationships, or conflicts of interest to disclose.
Author Contributions
Conceptualization, Data collection, Data analysis and interpretation, Writing, Critical revision of the manuscript, Approval of the final 
version: YSM.
Cite as: 
Mousa YS. Autoimmune lymphoproliferative syndrome (ALPS): a case report. Int J Med Students. 2016 Sep-Dec;4(3):123-6.
tations. N Engl J Med. 2004 Sep 30;351(14): 1409-18. 
7. Bleesing JJ. Sorting out the causes of ALPS. J Pediatr. 2005 Nov;147(5):571-4. 
8. Rossler J, Enders A, Lahr G, Heitger A, Winkler K, Fuchs H, et al. Identical 
phenotype in patients with somatic and germline CD95 mutations requires 
a new diagnostic approach to autoimmune lymphoproliferative syndrome. J 
Pediatr. 2005 Nov;147(5):691-4. 
9. Dowdell KC, Niemela JE, Price S, Davis J, Hornung RL, Oliveira JB, et al. So-
matic FAS mutations are common in patients with genetically undefined au-
toimmune lymphoproliferative syndrome. Blood. 2010 Jun 24;115(25):5164-9. 
10. Teachey DT, Seif AE, Grupp SA. Advances in the management and unders-
tanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol. 
2010 Jan;148(2):205-16. 
11. Wei A, Cowie T. Rituximab responsive immune thrombocytopenic purpura 
in an adult with underlying autoimmune lymphoproliferative syndrome due 
to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene. Eur J Haematol. 
2007 Oct;79(4):363-6. 
12. Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. 
Revised diagnostic criteria and classification for the autoimmune lymphopro-
liferative syndrome (ALPS): report from the 2009 NIH International Workshop. 
Blood. 2010 Oct 7;116(14):e35-40. 
13. Bleesing JJ. Autoimmune lymphoproliferative syndrome (ALPS). Curr 
Pharm Des. 2003;9(3):265-78. 
14. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, et 
al. Fas preassociation required for apoptosis signaling and dominant inhibi-
tion by pathogenic mutations. Science. 2000 Jun 30;288(5475):2354-7. 
15. Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, et al. Defec-
tive CD95/APO-1/Fas signal complex formation in the human autoimmune 
lymphoproliferative syndrome, type Ia. Proc Natl Acad Sci U S A. 1999 Apr 
13;96(8):4552-7. 
16. Yeh S, Li Z, Sen HN, Lim WK, Gill F, Perkins K, et al. Scleritis and multiple 
systemic autoimmune manifestations in chronic natural killer cell lympho-
cytosis associated with elevated TCRalpha/beta+CD3+CD4-CD8- double-nega-
tive T cells. Br J Ophthalmol. 2010 Jun;94(6):748-52. 
17. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Jr., Crowther MA, et al. 
The American Society of Hematology 2011 evidence-based practice guideline 
for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190-207. 
18. Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, et al. The de-
velopment of lymphomas in families with autoimmune lymphoproliferative 
syndrome with germline Fas mutations and defective lymphocyte apoptosis. 
Blood. 2001 Jul 1;98(1):194-200. 
19. Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, et al. Use of my-
cophenolate mofetil for chronic, refractory immune cytopenias in children 
with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005 
May;129(4):534-8. 
